Comparing the Extent to Which Maridebart Cafraglutide (AMG 133) is Made Available in the Body When Administered Using Two Subcutaneous (SC) Presentations

Clinical trial NCT07226778 · COMPLETED

Trial details

NCT number: NCT07226778
Sponsor: Amgen
Status: COMPLETED
Phase: Phase 1
Study type: INTERVENTIONAL

Overweight Obesity

Start date: 2025-10-10
Primary completion: 2026-05-28
Enrollment: 348

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.